In HCC mouse models, this intervention reduces liver tumor burden by inhibiting the TLR4/NF-κB axis, consistent with its ability to dampen inflammatory signaling and restrict tumor cell migration [64,65]. This evidence concerns the gene TLR4 and hepatocellular carcinoma.